Load More Posts

Recent Posts



Latest from the NCI

  • Home Is Where the Heart Is
    Dr. Ned Sharpless discusses his return as NCI director after serving as acting commissioner of the Food and Drug Administration for 7 months. Read more »
  • Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer
    A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer. Read more »
  • PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
    In three large clinical trials of women with newly diagnosed ovarian cancer, treatment with a PARP inhibitor as first-line therapy, maintenance therapy, or both, extended the length of time before participants’ cancers came back or got worse. Read more »
  • Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma
    Results from a new study suggest a potential way to improve the effectiveness of CAR T-cell therapy for multiple myeloma. The approach relies on a class of drugs called gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer’s disease. Read more »
  • Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from Chemo
    A TAILORx analysis shows women with early-stage breast cancer and high recurrence scores on the Oncotype DX who received chemotherapy with hormone therapy had better long-term outcomes than what would be expected from hormone therapy alone. Read more »
  • Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells
    Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions. Read more »
  • HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV Infections
    Oral HPV infections cause over 70% of all oropharyngeal cancers in the United States. In a new study of adults aged 18‒59, the rate of HPV vaccination rose from 0% to 6% for men, while oral HPV infections fell by 37% among unvaccinated men. Read more »
  • New on NCI's Websites for October 2019
    NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of October 2019. Read more »


As long as cancer persists, none of us can truly rest. It doesn’t take much to change a life, Get in touch today and start making the difference.

Contact US